SEC Form 4 · accession 0000357097-16-000207
Fibrocell Science, Inc. · FCSC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Michael Maslowski
Officer — CEO · Director
Period of report
Dec 16, 2016
Accepted (ET)
Dec 19, 2016 · 8:05 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000357097
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF2,F1 | $0.6625 | Dec 16, 2016 | A | 250,000 | A | — | Dec 16, 2026 | Common Stock | 250,000 | 250,000 | D |
Explanation of responses
- F1The options set forth in this table vest as follows: (i) 62,500 shares on December 16, 2017 and (ii) 15,625 for each of twelve quarterly installments beginning on March 16, 2017 and ending on December 16, 2019 provided the reporting person is employed by the Company on each vesting date.
- F2The options were issued in connection with the reporting person's employment service to the Company.